XT
ONCT

XTX Topco’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

XTX Topco’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-975
Closed -$10.5K – 2489
2023
Q4 		$10.5K Buy
+975
New +$7.02K ﹤0.01% 1425
2022
Q1 		– Sell
-575
Closed -$26K – 1024
2021
Q4 		$26K Buy
+575
New +$38.7K 0.01% 613

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

XTX Topco's ONCT Position: Q1 2024 in Review

XTX Topco sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 975 shares — an estimated $10.5K sold.

XTX Topco first reported a position in ONCT in Q4 2021 and held it in 2 quarters. The position peaked at $26K in Q4 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • XTX Topco reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • XTX Topco sold 975 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $10.5K.
  • XTX Topco first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • XTX Topco's Oncternal Therapeutics, Inc. Common Stock position peaked at $26K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on XTX Topco's 13F filing for Q1 2024, filed 13 May 2024.